Elevance Health, Inc. $ELV Holdings Lifted by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC raised its position in Elevance Health, Inc. (NYSE:ELV) by 58.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,295 shares of the company’s stock after purchasing an additional 19,339 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Elevance Health were worth $18,332,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Elevance Health during the second quarter worth approximately $1,148,379,000. Artisan Partners Limited Partnership increased its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after acquiring an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its position in Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after acquiring an additional 798,457 shares during the period. Beutel Goodman & Co Ltd. bought a new stake in Elevance Health during the 2nd quarter valued at $293,141,000. Finally, Brave Warrior Advisors LLC boosted its position in Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after acquiring an additional 724,349 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wolfe Research set a $425.00 price target on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Jefferies Financial Group cut their price objective on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Mizuho reduced their price objective on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Truist Financial decreased their target price on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Wells Fargo & Company lowered their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Trading Down 2.7%

Shares of NYSE:ELV opened at $286.23 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market capitalization of $63.17 billion, a price-to-earnings ratio of 11.39, a PEG ratio of 1.57 and a beta of 0.51. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a 50 day moving average price of $322.20 and a 200 day moving average price of $332.71.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.72 per share. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is currently 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.